A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration

Abstract
The commercial immune serum globulin (ISG) product is suitable for use in passive immunization only by i.m. administration; i.v. use causes vasomotor side reactions. The functional characterization is reported of a chemically modified ISG (MISG) that is essentially free of nonspecific complement-binding activity and contains no new antigenic determinants. The half-life values for MISG given i.v. to rabbits, guinea pigs and humans are not different from that of ISG. The MISG fulfills the in vitro and in vivo criteria of stability, safety, function and half-life, making it suitable for human i.v. administration.